From Financial Modeling Prep: 2025-05-27 06:45:00

Sanofi and Vietnam Vaccine JSC inaugurate a new vaccine facility in Vietnam, capable of producing various vaccine platforms, including mRNA formulations. The facility aims to boost COVID-19 booster rollout and enhance regional vaccine security, with an initial output of 50 million doses per year, set to expand to 100 million by 2027.

Sanofi will transfer biomanufacturing expertise to VNVC, strengthening Vietnam’s pharmaceutical sector. The facility’s output is crucial for routine immunizations and pandemic response, supported by Sanofi’s strong financial position with an AA- corporate rating and €15 billion in cash reserves.

In the context of Asia’s growing pharmaceutical industry, the new facility positions Sanofi and VNVC at the forefront of regional vaccine supply resilience. By increasing local production capacity, the joint venture enhances Southeast Asia’s self-sufficiency in critical biologics, leveraging Sanofi’s financial strength for future expansions.



Read more at Financial Modeling Prep:: Sanofi and VNVC Open Vaccine Manufacturing Hub in …